(Q46856129)

25 December 2017

title

Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer (English)

1 reference

25 December 2017

4

Eric P Winer

1 reference

25 December 2017

Aman U Buzdar

series ordinal

1

object named as

Aman U Buzdar

1 reference

25 December 2017

author name string

R Charles Coombes

series ordinal

2

1 reference

25 December 2017

Paul E Goss

series ordinal

3

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

25 December 2017

published in

Cancer

1 reference

25 December 2017

volume

112

1 reference

25 December 2017

issue

3 Suppl

1 reference

25 December 2017

page(s)

700-709

1 reference

25 December 2017

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

Peripheral bone status in rheumatoid arthritis evaluated by digital X-ray radiogrammetry and compared with multisite quantitative ultrasound

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23193

7 January 2021

Identifiers

DOI

10.1002/CNCR.23193

1 reference

25 December 2017

PubMed ID

18072256

1 reference

25 December 2017